ABCL - AbCellera Biologics GAAP EPS of $0.08 beats by $0.03 revenue of $101.38M beats by $18.02M November, 08 2022 04:15 PM AbCellera Biologics Inc. AbCellera Biologics press release ( NASDAQ: ABCL ): Q3 GAAP EPS of $0.08 beats by $0.03 . Revenue of $101.38M beats by $18.02M . For further details see: AbCellera Biologics GAAP EPS of $0.08 beats by $0.03, revenue of $101.38M beats by $18.02M